Alpha-9 Oncology

Alpha-9 has clinical and preclinical programs and lists BD@a9oncology.com for partnership inquiries.

Alpha-9 Oncology dosed the first participant in a Phase 1 study of 68Ga-A9-3202, a radiodiagnostic targeting MC1R for imaging locally advanced cancer.

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company developing targeted cancer therapies. The company announced Paul Blanchfield’s appointment as Chief Executive Officer and a member of the Board of Directors.

Alpha-9 Oncology announced a $175 million Series C financing to support the progression of its pipeline.

ITM Isotope Technologies Munich SE and Alpha-9 Oncology signed a global master clinical supply agreement to support development of Alpha-9’s programs.

Alpha-9 Oncology is hiring an associate director of regulatory affairs to support its clinical pipeline and help develop global regulatory strategy and submission plans.

Alpha-9 Oncology is hiring a director of total rewards and people operations to lead global rewards and people operations programs.

Alpha-9 Oncology has a talent network and says its mission is to advance radiopharmaceuticals to improve outcomes for patients with cancer.

The Alpha-9 team has decades of experience in peptide chemistry, cancer imaging, and radiopharmaceutical development.

Radiopharmaceuticals selectively deliver radiation to cancer cells. Alpha-9 has deep expertise in peptides, peptidomimetics, and small molecules.

Find contact information for Alpha-9 Oncology, developing new medicines using radiopharmaceuticals to help cancer patients.

Through peptide engineering and iterative design, Alpha9 Oncology creates highly selective, potent radiopharmaceuticals for cancer patients.

The website may store or retrieve information in a visitor’s browser, mostly in the form of cookies.

Alpha-9 Oncology Inc. and its affiliates process personal data for different purposes and describe that processing in their privacy policy.

Alpha-9 Oncology states that use of its website is subject to its terms of use and that accessing or using the site signifies agreement to those terms.